company

Epigenetics meets AI.
Medicine meets the
future.

Humanity is now beginning to unravel the root causes of aging—and learning how to reverse them.

Conventional medicine has long focused on treating illness only after it occurs.

Epigenetics, the mechanism that controls gene expression after birth, combined with our proprietary large-scale AI foundation model.Integrating these to realize precision predictive medicine.

Predicting future risks and delivering certainty for lifelong health.Extending human healthspan, bringing the gap between healthspan and lifespan ever closer to zero.

For a world where aging brings nothing but joy.

Company Profile

Company Name

Epigenetic AI Inc.

Established

June 3, 2025

Representatives

Makoto Koyama, Co-Founder/Co-CEO

Taizo Son, Co-Founder/Co-CEO

Location

Atagoyama PREX 10F, 3-25-31 Nishi-Shinbashi, Minato-ku, Tokyo

Advisory Board

Sharing Epigenetic AI's vision for the future, top scientists representing various fields in Japan have joined us. They support the reliability and scientific foundation of the services we provide.
Chairman
Toshikazu Yoshikawa
M.D., Ph.D.

Emeritus Professor, Kyoto Prefectural University of Medicine

Honorary Chairman, Japanese Society of Anti-Aging Medicine

Preventive & Preemptive Healthcare Advisor
Hiroshi Itoh
M.D., Ph.D.

Specially Appointed Professor
(full time)
Center for Preventive Medicine,
Keio University

Professor Emeritus of Keio University

Intervention Support AI Advisor
Yasushi Okuno
Ph.D.

Professor, Kyoto University

Omics Analysis & Aging Control Advisor
Takehiko Kobayashi
Ph.D.

Professor, University of Tokyo

Preventive & Preemptive Healthcare Advisor
Shigeo Horie
M.D., Ph.D.

Endowed Chair Professor, Juntendo University

Longevity Control Advisor
Tamotsu Yoshimori
Ph.D.

Professor Emeritus, The University of Osaka